Last updated: February 1, 2024
Sponsor: Augenklinik Zurich West
Overall Status: Active - Recruiting
Phase
N/A
Condition
Aging
Geographic Atrophy
Macular Degeneration
Treatment
Virtual Reality (VR) Contrast Function Test
Clinical Study ID
NCT06241625
APL-GA-001
Ages 50-105 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Subjects ≥18 years of age diagnosed with AMD
- Subject Snellen BCVA score is 20/100 or better
- Ability to undergo quality optical coherence tomography (OCT) imaging
- Willing and able to give written informed consent
Exclusion
Exclusion Criteria:
- Unwilling to use headset
- Previous negative experience with a VR headset (eg, motion sickness, discomfort)
- Any known oculomotor impairment that would impact the ability of the subject toperform the tasks (eg, nystagmus, proptosis, apraxia of eyelid opening)
- Any manifest neurological or cognitive condition that would impair the subject'sunderstanding or performance on the test (eg, Alzheimer's disease, Parkinson'sdisease)
- Any physical limitations that would prohibit the use of the VR headset (eg, neckproblems)
Study Design
Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Virtual Reality (VR) Contrast Function Test
Phase:
Study Start date:
October 20, 2022
Estimated Completion Date:
July 31, 2024
Study Description
Connect with a study center
Augenklinik Zurich West
Zürich, Zurich 8047
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.